Total
0
Shares
ice - The Market Herald
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) anti-infective RECCE 327 (R327) has shown bactericidal activity against all six antibiotic-resistant ESKAPE pathogens
  • The ESKAPE pathogens are a group of antibiotic-resistant bacteria that 'escape' the biocidal action of antibiotics
  • Notably, the pathogens are responsible for 42.2 per cent of blood infections, around 50 million infections each year
  • Recce found that the bactericidal activity of R327 showed a 99.9 per cent reduction in the number of colony-forming units over 24 hours when used against all six strains
  • Just as the market opens this morning, Recce is in the grey and trading at $1.13

Recce Pharmaceuticals (RCE) anti-infective, RECCE 327 (R327), has shown bactericidal activity against all six antibiotic-resistant ESKAPE pathogens.

The ESKAPE pathogens are a group of antibiotic-resistant bacteria that 'escape' the biocidal action of antibiotics. Collectively, the pathogens are responsible for over 720,000 hospital infections each year in the United States.

Recce found that the bactericidal activity of R327 showed a 99.9 per cent reduction in the number of colony-forming units over 24 hours against all six strains at various concentrations and times.

The study was conducted by an independent contract research organisation to assess the in-vitro efficiency of R327 against all ESKAPE pathogen bacterial strains.

R327 is a synthetic anti-infective that has the potential to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.

ESKAPE pathogens are responsible for 42.2 per cent of blood infections, around 50 million infections each year, resulting in one in five deaths in the community or one in three deaths in hospitals.

"We are encouraged by the data from this study and will continue to explore the potential of R327 to treat hospital-acquired infections," CEO James Graham said.

"Antimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug resistance," he added.

"Additionally, with R327 effective against two more priority pathogens listed by the WHO, we believe reinforces the potential of R327 to treat some of the greatest threats to human health," he concluded.

Just as the market opens this morning, Recce is in the grey and trading at $1.13 per share at 10:03 am AEST.

RCE by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.